Wasatch BioLabs and Agilent announced a co-marketing agreement for a targeted nanopore methylation sequencing assay developed jointly and available under early access. The service pairs Wasatch’s sample-to-sequencer workflows with Agilent’s platform reach to deliver methylation‑focused assays for research and clinical translational work. The collaboration aims to accelerate adoption of targeted nanopore methylation profiling. Early access availability positions the assay for rapid uptake by labs interested in epigenetic biomarkers; broader commercialization and regulatory positioning will determine its role in diagnostics pipelines.